VRC rapid manufacturing response: NCI federally funded research and development center (ffrdc) contract
Active Awarded Last action
- Contract number
- 75N91022F00002
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $20,909,200
Award facts
- Contract value 97% obligated
-
- $20,909,200.00 Current, with exercised options
- $21,593,558.00 Potential, with all options
- Completion date 71% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $6,454,771 | |
| Other Administrative Action | $1,756,721 | |
| Original award | $12,697,708 |
About this award
This federal contract award is for the "VRC RAPID MANUFACTURING RESPONSE: NCI FEDERALLY FUNDED RESEARCH AND DEVELOPMENT CENTER (FFRDC) CONTRACT" awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency. The $21,593,558.00 cost-plus-fixed-fee contract has an ultimate completion date of July 2, 2028 and was awarded on September 16, 2022 to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc.
Leidos Biomedical Research Inc. serves as a Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute (NCI), providing a range of biomedical research and facilities support services to federal agencies, particularly the National Institutes of Health (NIH). This contract does not have a set-aside designation. The scope of work likely includes COVID-19 research, GMP manufacturing, and support for programs such as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative and the Clinical Proteomic Tumor Analysis Consortium (CPTAC).
Quick answers
Who was awarded contract 75N91022F00002?
75N91022F00002 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2022.
How much is contract 75N91022F00002 worth?
The government has obligated $20,909,200 on 75N91022F00002. Its potential value, with all options, is $21,593,558.
Which agency awarded contract 75N91022F00002?
National Cancer Institute (National Institutes of Health) awarded 75N91022F00002, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91022F00002 an order under another contract?
Yes. 75N91022F00002 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00002 competed?
The extent of competition for 75N91022F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award